Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREOPANC-3: Perioperative versus adjuvant FOLFIRINOX in resectable pancreatic cancer
2020-005141-16Phase 3Active
- Sponsor
- Erasmus MC
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of FOLFIRINOX in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Erasmus MC. Primary endpoint: overall survival. Started Jan 2021; status: active.
02
Drugs
FOLFIRINOX
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2020-005141-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005141-16.